Skip to main content
Biocartis Group NV logo

Biocartis Group NV — Investor Relations & Filings

Ticker · BCART ISIN · BE0974281132 LEI · 549300J4HOJL5KG8HY54 BR Manufacturing
Open in API
Filings indexed 636 across all filing types
Latest filing 2023-04-28 Share Issue/Capital Cha…
Country BE Belgium
Listing BR BCART

About Biocartis Group NV

https://www.biocartis.com/en

Biocartis Group NV is a molecular diagnostics company that develops and commercializes its proprietary Idylla™ platform. This fully automated, sample-to-result system is designed to provide fast, easy, and actionable molecular diagnostic results, making advanced testing accessible to laboratories of any size. The company's primary focus is in the field of oncology, offering a menu of tests that support the diagnosis and treatment of various cancers, including lung, colorectal, melanoma, and breast cancer. Biocartis aims to enable personalized medicine for patients by providing universal access to molecular testing. The company also collaborates with pharmaceutical partners in the development of companion diagnostics.

Recent filings

Filing Released Lang Actions
20230427 PR Outstanding shares_Apr2023_NL_FINAL.pdf
Share Issue/Capital Change Classification · 95% confidence The document is titled "PERSBERICHT GEREGLEMENTEERDE INFORMATIE" (Regulated Information Press Release) and its main subject is the "Openbaarmaking van uitstaande stemrechtverlenende effecten" (Disclosure of outstanding voting securities). It details the issuance of new shares due to debt conversion and convertible bond conversion, and subsequently updates the total outstanding capital, voting rights, and potential future issuances based on various plans and loan agreements. This type of mandatory disclosure regarding changes in the total number of shares and voting rights, often triggered by specific events like debt-for-equity swaps, falls under notifications related to capital structure changes or major shareholding changes. Since it explicitly details the total number of voting rights and the mechanism for calculating them, it strongly relates to share capital changes. The closest fit among the provided codes is 'SHA' (Share Issue/Capital Change) or potentially 'MRQ' (Major Shareholding Notification) if it were focused on a shareholder crossing a threshold, but here the focus is on the company's total capital structure update following transactions. Given the detailed breakdown of capital structure changes resulting from debt conversion, 'SHA' is the most appropriate classification for a formal announcement detailing the resulting total share count and potential future issuances. It is not an ER (Earnings Release), CT (Call Transcript), or 10-K (Annual Report). It is a specific regulatory disclosure about the capital base.
2023-04-28 Dutch
230417 PR Q1 2023 Business Update_ENG_FINAL.pdf
Earnings Release Classification · 98% confidence The document is explicitly titled "PRESS RELEASE REGULATED INFORMATION" and provides a business update for the "first quarter of 2023" including key financial metrics like revenue, gross margin, and EBITDA for that period. It also reiterates the outlook for the full year 2023 and includes a financial calendar listing the date for the 'H1 2023 results'. This structure—a press release summarizing period-specific financial performance—is the hallmark of an Earnings Release (ER). It is not the comprehensive, detailed report (10-K or IR), nor is it a transcript (CT) or a management discussion (MDA), although it contains elements of MDA. The primary function is the initial announcement of period results. Q1 2023
2023-04-20 English
230417 PR Q1 2023 Business Update_NL_FINAL.pdf
Earnings Release Classification · 98% confidence The document is titled with a clear reference to reporting results for the first quarter of 2023 ("Biocartis rapporteert resultaten eerste kwartaal 2023"). It contains key financial highlights (revenue, gross margin, EBITDA) for the period and management commentary on these results, along with future outlooks. This structure is characteristic of an Earnings Release (ER), which provides the initial announcement of periodical financial results, often summarized before the full quarterly report (IR) is released. The document is relatively short and focuses on the highlights and management discussion, fitting the ER definition better than the comprehensive Interim Report (IR). Q1 2023
2023-04-20 Dutch
230411 PR CEO_ENG_FINAL.pdf
Board/Management Information Classification · 100% confidence The document is explicitly labeled as a "PRESS RELEASE INSIDE INFORMATION/ REGULATED INFORMATION" dated April 11, 2023. The core content announces a change in senior management: the appointment of a new CEO (Roger Moody) and the transition of the current CEO (Herman Verrelst) to Executive Chairman. This directly corresponds to the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2023-04-11 English
230411 PR CEO_NL_FINAL.pdf
Board/Management Information Classification · 100% confidence The document is titled "PERSBERICHT VOORWETENSCHAP / GEREGLEMENTEERDE INFORMATIE" (Press Release for Information / Regulated Information) and announces significant changes in senior management: the appointment of a new CEO (Roger Moody) and the transition of the current CEO (Herman Verrelst) to Executive Chairman. This content directly relates to changes in the company's board of directors or senior management. This aligns perfectly with the definition for Board/Management Information (MANG). It is not an earnings release (ER), a full annual report (10-K), or a general regulatory filing (RNS), as it concerns a specific management change.
2023-04-11 Dutch
AGM 2023 - Attendance Form (DUT ENG) (final).pdf
AGM Information Classification · 98% confidence The document is explicitly titled "DEELNEMINGSFORMULIER VOOR HOUDERS VAN EFFECTEN" / "ATTENDANCE FORM FOR SECURITIES HOLDERS" for the "Gewone algemene aandeelhoudersvergadering" / "Annual shareholders' meeting". This form is used by shareholders to register their intent to attend the AGM. While it relates to the AGM, it is not the presentation materials (AGM-R) or the proxy solicitation materials (PSI), but rather the specific administrative form required for attendance. However, among the provided codes, 'AGM-R' (AGM Information) is the closest category for materials directly related to the Annual General Meeting process, often encompassing all related administrative documents like attendance forms, especially when a more specific 'Proxy Form' code isn't available or applicable (PSI is for solicitation/information statements). Given the context of an official meeting attendance document, AGM-R is the most appropriate fit.
2023-04-11 Dutch

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.